PharmaFocus Today – Page 155 – media

FDA Approves Imbruvica Label Expansion to Include Oral Suspension Formulation

Don Tracy, Associate Editor New label marks the first Bruton’s tyrosine kinase inhibitor to be approved with an oral suspension formulation. The FDA has approved an addendum to the Imbruvica (ibrutinib) label to include an oral suspension formulation across the drug’s indications. Johnson & Johnson (J&J), in partnership with Pharmacyclics LLC, an AbbVie Company, announced that the new formulation is approved to treat patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Waldenström’s macroglobulinemia (WM), and chronic graft versus host disease (cGVHD) following the failure of one or more lines of systemic therapy. This option is designed for patients who have difficulty swallowing pills, part of J&J’s ongoing efforts to provide multiple patient-friendly treatment options, the company stated in a press release.1 “As the most comprehensively studied therapy in its class, Imbruvica has helped change the standard of care for adults living with certain blood cancers and cGVHD. Nearly 300,000 ...
- Source: drugdu
- 131
- February 29, 2024
Allecra Therapeutics’ Exblifep Approved by FDA for Complicated Urinary Tract Infections

Davy James The FDA granted Allecra with a five-year marketing exclusivity extension for Exblifep (cefepime/enmetazobactam) through the Generating Antibiotic Incentives Now Act. The FDA has approved Allecra Therapeutics’ Exblifep (cefepime/enmetazobactam) for the treatment of complicated urinary tract infections (cUTIs), including the kidney infection pyelonephritis, in patients aged 18 years and older.1 The FDA also granted Allecra with a five-year marketing exclusivity extension for the β-lactam/β-lactamase inhibitor combination through the Generating Antibiotic Incentives Now Act (GAIN Act), which is legislation that incentivizes the development of new anti-infective treatments. “Receiving FDA approval is a tremendous achievement for Allecra and a testament to the hard work and dedication of a small, yet highly focused team of individuals. I extend my sincere congratulations to my colleagues Omar Lahlou and Patrick Velicitat for their leadership and oversight throughout this whole process,” Iain Buchanan, supervisory board member of Allecra Therapeutics, said in a press release. “As ...
- Source: drugdu
- 117
- February 29, 2024
China’s marketed drug patent information registration platform has a new “legal document submission module”

On February 26, the Center of Drug Evaluation of the NMPA issued the “Notice on Setting up a Legal Document Submission Module on the Patent Information Registration Platform for Marketed Drugs in China” (hereinafter referred to as the “Notice”). The following is the original content of the Notice: Since the implementation of the “Implementation Measures for the Early Resolution Mechanism for Drug Patent Disputes (Trial)”, patent disputes have been resolved simultaneously during the review of generic drug marketing applications. In order to further improve work efficiency and facilitate patent holders, interested parties and generic drug applicants to submit relevant legal documents, a legal document submission module has been set up on the Chinese marketed drug patent information registration platform. From the date of issuance of this notice, patentees, interested parties or generic drug applicants can directly submit an “application for setting a waiting period”, acceptance notice, judgment, decision or settlement ...
- Source: drugdu
- 90
- February 29, 2024
Inclusion of noncommunicable disease care in response to humanitarian emergencies will help save more lives

Noncommunicable diseases (NCDs), such as cardiovascular disease, cancer, chronic respiratory disease and diabetes, are responsible for 75% of deaths worldwide. People affected by humanitarian emergencies are at increased risk of NCDs. It is estimated that strokes and heart attacks are up to 3 times more likely following a disaster. However, care and treatment for NCDs are often not included as a standard part of humanitarian emergency preparedness and response, which focus on the most immediate needs. To support integration of essential services for NCDs into emergency preparedness and humanitarian response, the World Health Organization (WHO), the Kingdom of Denmark, the Hashemite Kingdom of Jordan, the Republic of Kenya, and UNHCR, the UN Refugee Agency, are jointly convening a global high-level technical meeting on NCDs in humanitarian settings on 27-29 February in Copenhagen, Denmark. Humanitarian emergencies in recent years are becoming more complex and interconnected. Hunger and shortages of essential goods ...
- Source: drugdu
- 121
- February 29, 2024
China Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split

HAIKOU, China, Feb. 24, 2024 /PRNewswire/ — China Pharma Holdings Inc. (“China Pharma” or the “Company”) (NYSE American: CPHI) reported that it expects to implement a 1-for-5 reverse stock split on its common stock effective Wednesday, March 6, 2024, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the common stock will continue on the NYSE American under the symbol “CPHI”. The new CUSIP number for the common stock following the reverse stock split is 16941T-302. The reverse stock split at a ratio of 1-for-5 shares was approved by the Company’s Board of Directors through unanimous written consent on October 16, 2023 and adopted by the Company’s stockholders through Annual Meeting for the fiscal year ended on December 31, 2022, which was held on December 17, 2023. Upon the effectiveness of the reverse stock split, every 5 shares of the Company’s issued ...
- Source: drugdu
- 94
- February 29, 2024
Hengrui Pharmaceuticals’ PD-L1 Inhibitor Adebelizumab Combined with HER2 ADC SHR-A1811 Approved for Breast Cancer Clinical Treatment

Recently, Hengrui Pharmaceuticals’ subsidiaries, Shanghai Shengdi Pharmaceuticals Co., Ltd. and Suzhou Shengdia Biopharmaceuticals Co., Ltd. received the Notice of Approval for Drug Clinical Trial approved by the State Drug Administration, which authorizes the company to carry out the clinical trial of adelberizumab in combination with SHR-A1811 for the treatment of breast cancer. According to the data released by the International Agency for Research on Cancer (IARC) of the World Health Organization in 2020, breast cancer has become the world’s number one malignant tumor and is the most common malignant tumor in women. Statistics show that in 2020, there were about 2.26 million newly diagnosed cases of female breast cancer and 685,000 deaths worldwide, ranking first in female malignant tumor morbidity and mortality. The incidence and mortality rates of breast cancer worldwide vary according to regional distribution. In China, the 2020 China Cancer data show that the incidence rate of breast ...
- Source: drugdu
- 131
- February 29, 2024
Sponge-on-a-string test to benefit NHS patients with oesophageal cancer

Eight out of ten patients who took the test were discharged without needing further testing The NHS has announced that a simple sponge-on-a-string test developed by researchers from the early cancer institute at the University of Cambridge will replace the need for endoscopy to prevent oesophageal cancer. The NHS trialled the test to help diagnose Barrett’s oesophagus, a condition that affects the food pipe and can lead to oesophageal cancer. Responsible for around 9,200 new cases every year in the UK, oesophageal cancer occurs in the long, hollow tube that runs from the throat to the stomach, known as the oesophagus. During the pandemic, the NHS began piloting the test at 30 hospitals across 17 areas in England, including Manchester, Plymouth, London, Kent and Cumbria. The test requires the patient to swallow a small capsule-shaped device containing a small sponge that collects cell samples for analysis before being extracted via ...
- Source: drugdu
- 139
- February 29, 2024
UK and Netherlands researchers call for funding to investigate cancer treatments

The white paper outlines three strategic recommendations to support further research Researchers from King’s College London and Erasmus MC in the Netherlands have called for further funding support in a recently published white paper to investigate the use of radioactive cancer-targeted drugs to improve cancer treatments. The white paper, Unlocking the Full Potential of Cancer Treatments Using Targeted Radionuclide Therapy through Netherlands-UK Partnerships, outlined three strategic recommendations to achieve this. Most radioactive drugs are used to specifically deliver a radiation dose to cancer cells to produce a therapeutic effect. They are used to treat the disease areas identified on medical scans but can also specifically target the microscopic tumour deposits, which are involved in the progression of the disease. More specifically, targeted radionuclide therapy, a type of radiation therapy, is effective to treat prostate cancer and some other types of cancer where radionuclide, a radioactive chemical, is linked to cell-targeting ...
- Source: drugdu
- 154
- February 29, 2024
New Blood Testing Method Detects Potent Opioids in Under Three Minutes

Fentanyl, an opioid 50 times more potent than heroin, presents a major risk to public health. In recent years, there’s been a growing concern over the rise in fentanyl use among drug users. Annually, this potent drug is responsible for thousands of overdose deaths globally. In response to this crisis, a breakthrough in drug testing has been achieved. Now, researchers have developed a new blood testing method capable of detecting powerful opioids, including fentanyl, more rapidly than traditional methods, thereby offering a potential lifeline in overdose situations. This innovative method developed by a team at the University of Waterloo (Ontario, Canada) can simultaneously analyze up to 96 blood samples for the presence of opioids like fentanyl in less than three minutes, a rate that’s double the speed of existing methods. To conduct the test, a small volume of blood is placed into each well of a 96-well plate, which also ...
- Source: drugdu
- 120
- February 28, 2024
Alzheimer’s Blood Test Could Soon Replace Invasive Spinal Taps and Brain Scans

Historically, Alzheimer’s disease was primarily diagnosed based on observable symptoms, particularly when individuals started exhibiting memory and cognitive difficulties. However, it’s been revealed through research that up to a third of individuals diagnosed with Alzheimer’s based solely on cognitive symptoms have been incorrectly diagnosed, with their symptoms stemming from other causes. The accurate identification of Alzheimer’s disease has become increasingly crucial, especially since the introduction of the first treatments that can slow the disease’s progression, along with other promising drugs currently in development. These treatments are potentially more effective when administered early, highlighting the need for early detection of the disease. Therefore, to qualify for Alzheimer’s therapies, patients must show cognitive impairment and test positive for amyloid plaques, which are distinctive to Alzheimer’s. Techniques like amyloid positron emission tomography (PET) brain scans, cerebrospinal fluid analyses, and blood tests are used to detect brain amyloid plaques. However, these are only employed ...
- Source: drugdu
- 164
- February 28, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.